Comparative Effectiveness of Levothyroxine, Desiccated Thyroid Extract, and Levothyroxine+Liothyronine in Hypothyroidism
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 2 of the 6 sources its claims cite were checked for support.
Abstract
Introduction: Studies comparing levothyroxine (LT4) therapy with LT4 + liothyronine (LT3) or desiccated thyroid extract (DTE) did not detect consistent superiority of either treatment. Here, we investigated these therapies, focusing on the whole group of LT4-treated hypothyroid patients, while also exploring the most symptomatic patients. Methodology: Prospective, randomized, double-blind, crossover study of 75 hypothyroid patients randomly allocated to 1 of 3 treatment arms, LT4, LT4 + LT3, and DTE, for 22 weeks. The primary outcomes were posttreatment scores on the 36-point thyroid symptom questionnaire (TSQ-36), 12-point quality of life general health questionnaire (GHQ-12), the Wechsler memory scale-version IV (VMS-IV), and the Beck Depression Inventory (BDI). Secondary endpoints included treatment preference, biochemical and metabolic parameters, etiology of hypothyroidism, and Thr92Ala-DIO2 gene polymorphism. Analyses were performed with a linear mixed model using subject as a random factor and group as a fixed effect. Results: Serum TSH remained within reference range across all treatment arms. There were no differences for primary and secondary outcomes, except for a minor increase in heart rate caused by DTE. Treatment preference was not different and there were no interferences of the etiology of hypothyroidism or Thr92Ala-DIO2 gene polymorphism in the outcomes. Subgroup analyses of the 1/3 most symptomatic patients on LT4 revealed strong preference for treatment containing T3, which improved performance on TSQ-36, GHQ-12, BDI, and visual memory index (VMS-IV component). Conclusions: As a group, outcomes were similar among hypothyroid patients taking DTE vs LT4 + T3 vs LT4. However, those patients that were most symptomatic on LT4 preferred and responded positively to therapy with LT4 + LT3 or DTE.
Overview
CoChat Summary
## TL;DR
This prospective randomized double-blind crossover trial found no overall differences among levothyroxine (LT4), desiccated thyroid extract (DTE), and LT4+liothyronine in the full sample of 75 hypothyroid patients who completed the study. However, a subgroup analysis suggested that the most symptomatic patients on LT4 improved and preferred therapies containing T3 (DTE or LT4+LT3).
## Key findings
- 75 of 90 enrolled patients completed the study; 15 withdrew before randomization because of relocations and time conflicts.
- In the full cohort, there were no differences among treatments in the primary outcomes: TSQ-36, GHQ-12, BDI, or the 5 WMS-IV subdomains.
- Serum thyroid measures shifted as expected with T3-containing therapies: fasting total T3 was 30% to 50% higher and serum T4 was about 30% lower on DTE or LT4+LT3; the T4/T3 ratio dropped 38% with LT4+LT3 and 56% with DTE.
- In the subgroup analysis, the highest-symptom tercile on LT4 showed significant improvement after switching to LT4+LT3 (P = 0.0005) or DTE (P = 0.0008); the paper says these patients also preferred T3-containing therapy.
## Methods
- Design: Prospective, randomized, double-blind, crossover trial registered at ClinicalTrials.gov NCT02317926.
- Sample: 90 adults with primary hypothyroidism on stable LT4; 75 completed. Participants were mostly Caucasian (77.3%), female (77.3%), average age 50 years, and about 180 pounds.
- Analysis: Mixed-effects models for treatment comparisons; Tukey-adjusted contrasts for between-treatment differences; Plackett-Luce model for treatment preference; subgroup tercile analyses with Kruskal-Wallis, Dunn tests, Holm adjustment, and one-sample exact Wilcoxon tests.
## Limitations
- The paper explicitly states that a significant limitation was that the most notable findings came from a subanalysis not included in the primary outcomes, using a smaller subset and a between-subjects analysis.
- The authors note the study was powered for within-subject differences in TSQ scores, not for the subgroup comparisons, so the subgroup results are less definitive.
- Evident from the text: the subgroup findings may be affected by regression to the mean, which the authors discuss as a possible explanation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
2 Valid · 0 Not valid · 1 Not checked · 35 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This suggests that “responsiveness to therapy containing T3” depends on multiple factors, including genetic background, presence of comorbidities/autoimmune disorders, as well as other yet unidentified biological/environmental factors ( 25 ).”
What the sources say
- Partly supportedcites [25] Ettleson, 2020, Individualized therapy for hypothyroidism: is T4 enough for everyone?, J Clin Endocrinol Metab sourceExperimental — accuracy not yet measured
The Conclusions report an association between a genetic variant and enhanced response to combination therapy, and recommend screening future trial participants for genetic, autoimmune, and other interfering variables. The paper proposes that individual factors contribute to persistent symptoms on T4, but it does not establish that comorbidities or unidentified environmental factors determine responsiveness to T3-containing therapy. (LLM, conf=0.84)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“There is now a consensus that a fraction of the LT4-treated hypothyroid patients with normal serum TSH levels remains symptomatic ( 6 , 7 , 23 , 24 ).”
- Also stated in: § Discussion · plain
“In conclusion, some patients on LT4 therapy remain symptomatic despite normal serum TSH levels.”
What the sources say
- Not checked — no full text of the sourcecites [6] Saravanan, 2002, Psychological well-being in patients on ‘adequate’ doses of l-thyroxine: results of a large, controlled community-based questionnaire study, Clin Endocrinol (Oxf). source
- Not checked — no full text of the sourcecites [7] Wekking, 2005, Cognitive functioning and well-being in euthyroid patients on thyroxine replacement therapy for primary hypothyroidism, Eur J Endocrinol. source
- Not checked — no full text of the sourcecites [23] Peterson, 2018, An online survey of hypothyroid patients demonstrates prominent dissatisfaction, Thyroid. source
- Supportedcites [24] Peterson, 2016, Is a normal TSH synonymous with “euthyroidism” in levothyroxine monotherapy?, J Clin Endocrinol Metab. source
The Abstract says evidence suggests that a significant proportion of patients treated with LT4 continue to experience residual hypothyroid symptoms, despite treatment at doses that normalize serum TSH. This supports the cited sentence’s claim that some LT4-treated patients with normal TSH remain symptomatic. (LLM, conf=0.90)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Nonetheless, our findings are clear that no correlation between serum T3 and outcomes could be established in the present investigation, not even in the subanalyses.”
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the present investigation, the number of these patients was not sufficiently large to affect the outcomes of the whole group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“They also preferred therapy containing T3 or with DTE.”
- Also stated in: § Discussion · hedged
“These patients were also the ones that preferred and benefitted from switching to therapy containing T3, either DTE or LT4 + LT3 combination, suggesting that thyroid hormone signaling in a minority of the patients on LT4 remain subnormal and can be improved (perhaps restored) with therapy containing T3.”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Also stated in: § Discussion · hedged
9 more claims
Create a free account to see all 38 claims and every source verdict.
- It may state two separate claims as one. 19
- Probably not a substantial claim. 10
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“further trials of liothyronine/levothyroxine combination therapy, as well as the use of thyroid extracts, have recently been published, again with negative results. 43,62”
From Use of liothyronine (T3) in hypothyroidism: Joint British Thyroid Association/Society for endocrinology consensus statement (2023) · cites this paper as [43]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a three-arm, double-blind study of levothyroxine, levothyroxine-liothyronine, and DTE, outcomes were similar for all three treatment groups, although the most symptomatic individuals on levothyroxine at baseline responded to levothyroxine-liothyronine and DTE therapy.192”
From Hypothyroidism (2024) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There was no significant difference in Heart Rate, SHBG, TSH, Lipid profile, TSQ-36, and BDI Score.”
From Evaluating the effectiveness of combined T4 and T3 therapy or desiccated thyroid versus T4 monotherapy in hypothyroidism: a systematic review and meta-analysis (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most of the included studies are insignificant [9, 12–18] except for two studies, one showed a lower TSH, and the other showed a higher TSH [19, 20].”
From Evaluating the effectiveness of combined T4 and T3 therapy or desiccated thyroid versus T4 monotherapy in hypothyroidism: a systematic review and meta-analysis (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Almost all these blinded RCTs showed that QoL improved during combined liothyronine/levothyroxine treatment, but that it also improved to the same degree during levothyroxine monotherapy, demonstrating the strong placebo effect of thyroid hormones.”
From Use of liothyronine (T3) in hypothyroidism: Joint British Thyroid Association/Society for endocrinology consensus statement (2023) · cites this paper as [43]
Experimental — accuracy not yet measured
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032 · cited 2×
“The BDI is a self-rating scale of 21 items, in which scores of 10 or less indicate normal mood variation and scores of 11 or more reflect increasing levels of depression; clinically important depression is associated with scores of 20 or more (17,18).”
BackgroundMethodScoville, W. B. (1949) · Journal of neurosurgery · doi:10.3171/jns.1949.6.1.0065 · Cited by 7,380
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928 · cited 2×
“Several clinical trials addressed the question of whether residual symptoms could be resolved through the use of combination therapy with LT4 and LT3, but evidence of consistent superiority of combination therapy was not obtained (8,9).”
BackgroundResultSelf-citationChaker, L., Bianco, A. C., Jonklaas, J., & Peeters, R. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30703-1 · Cited by 1,159
Self-citationSaravanan, P., Chau, W. ‐., Roberts, N., Vedhara, K., Greenwood, R., & Dayan, C. M. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01654.x · Cited by 514 · cited 2×
“The existence of residual symptoms in LT4-treated patients was first documented through a patient survey (5) and later through questionnaires that evaluated thyroid-specific symptoms and quality of life (QoL) (6), as well as sophisticated cognitive tests (7).”
BackgroundL-Thyroxine Therapy in Subclinical Hypothyroidism: A Double-Blind, Placebo-Controlled Trial
COOPER, D. S., HALPERN, R., WOOD, L. C., LEVIN, A. A., & RIDGWAY, E. C. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-101-1-18 · Cited by 423 · cited 1×
“Because there are no well-validated and specific instruments to quantify the severity of hypothyroidism, we designed our own TSQ (12,17), a health-related QoL questionnaire, that was modeled after the hypothyroid-specific questionnaires developed by Jaeschke et al (20) and Cooper et al (21).”
MethodAoki, Y., Belin, R. M., Clickner, R., Jeffries, R., Phillips, L., & Mahaffey, K. R. (2007) · Thyroid · doi:10.1089/thy.2006.0235 · Cited by 390
Benson, N., Hulac, D. M., & Kranzler, J. H. (2010) · Psychological Assessment · doi:10.1037/a0017767 · Cited by 309 · cited 9×
“The WMS-IV Beginning of study period 114.7 ± 25.3 76.7 ± 16.3 83.6 ± 19.7 8.78 ± 1.74 End of study period 115.4 ± 25.1 77.3 ± 16.8 84.1 ± 19.6 8.82 ± 1.75 Abbreviations: DTE, desiccated thyroid extract; LT3, liothyronine; LT4, levothyroxine. included 5 subdomains: auditory memory index, visual memory index (VMI), visu…”
BackgroundMethodInfluentialWekking, E. M., Appelhof, B. C., Fliers, E., Schene, A. H., Huyser, J., Tijssen, J. G. P., & Wiersinga, W. M. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.02025 · Cited by 299 · cited 2×
“The existence of residual symptoms in LT4-treated patients was first documented through a patient survey (5) and later through questionnaires that evaluated thyroid-specific symptoms and quality of life (QoL) (6), as well as sophisticated cognitive tests (7).”
BackgroundParadigms of dynamic control of thyroid hormone signaling
Bianco, A. C., Dumitrescu, A., Gereben, B., Ribeiro, M. O., Fonseca, T. L., Fernandes, G. W., & Bocco, B. M. L. C. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00275 · Cited by 293 · cited 1×
“This apparent conundrum suggests that intracellular T3 levels, which are affected by both serum T3 and locally generated T3, might be playing a role (30).”
BackgroundSelf-citation
Research works printed but not linked: 3
- Roberts, Psychological problems in thyroid disease, Br Thyroid Foundation Newsl., 1996;18:3
- Wechsler, The Wechsler Memory Scalle-IV.
- McDowell, The General Health Questionnaire, Measuring Health. A guide to Rating Scales and Questionnaires.
Cited by
Hashimoto thyroiditis: an evidence-based guide: etiology, diagnosis and treatment
Klubo-Gwiezdzinska, J., & Wartofsky, L. (2022) · Polish Archives of Internal Medicine · doi:10.20452/pamw.16222 · Cited by 207
Primary hypothyroidism and quality of life
Hegedüs, L., Bianco, A. C., Jonklaas, J., Pearce, S. H., Weetman, A. P., & Perros, P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00625-8 · Cited by 144
Self-citationTaylor, P. N., Medici, M. M., Hubalewska-Dydejczyk, A., & Boelaert, K. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01614-3 · Cited by 128
Optimal thyroid hormone replacement
Jonklaas, J. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab031 · Cited by 89
Brain Fog in Hypothyroidism: What Is It, How Is It Measured, and What Can Be Done About It
Samuels, M. H., & Bernstein, L. J. (2022) · Thyroid · doi:10.1089/thy.2022.0139 · Cited by 64
“A Netherlands study found no impact of the polymorphism on response to LT4 monotherapy on HRQoL or executive function (58), and another study found no correlation between the Thy92Ala polymorphism and memory (48).”
Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer
Tang, L.-B., Peng, Y., Chen, J., Li, J.-T., Zheng, M.-M., Lv, W., Lu, C., Wei, X., Cai, D.-X., Guo, Z. J., et al. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01029-7 · Cited by 58
“Thus far, no reports exist of patients becoming intolerant of thyroid hormone-replacement therapy following ICI-induced loss of thyroid function 115,116 .”
The relevance of T3 in the management of hypothyroidism
Salvatore, D., Porcelli, T., Ettleson, M. D., & Bianco, A. C. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00004-3 · Cited by 41
Self-citationYi, W., Kim, B. H., Kim, M., Kim, J., Im, M., Ryang, S., Kim, E. H., Jeon, Y. K., Kim, S. S., & Kim, I. J. (2022) · Thyroid · doi:10.1089/thy.2021.0634 · Cited by 36
“17,18 Due to the increase in the prescription rate of LT4/LT3 combination therapy, concerns have been raised regarding the long-term safety outcomes of LT3 therapy in heart and bone diseases.”
Emerging Therapies in Hypothyroidism
Bianco, A. C. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-060622-101007 · Cited by 44
Self-citationAhluwalia, R., Baldeweg, S. E., Boelaert, K., Chatterjee, K., Dayan, C., Okosieme, O., Priestley, J., Taylor, P., Vaidya, B., Zammitt, N., et al. (2023) · Clinical Endocrinology · doi:10.1111/cen.14935 · Cited by 34
“42 12, 42, 43 Almost all these blinded RCTs At present in the United Kingdom, there is a 49 ‐ fold variation in the number of liothyronine prescriptions per 1000 levothyroxine prescriptions by local prescribing region.”
BackgroundThe Physiological Functions and Polymorphisms of Type II Deiodinase
Deng, Y., Han, Y., Gao, S., Dong, W., & Yu, Y. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1599 · Cited by 37
Critical Approach to Hypothyroid Patients With Persistent Symptoms
Biondi, B., Celi, F. S., & McAninch, E. A. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad224 · Cited by 34
Self-citationLan, H., Wen, J., Mao, Y., Huang, H., Chen, G., & Lin, W. (2022) · Clinical Endocrinology · doi:10.1111/cen.14742 · Cited by 26
Lawton, R. I., Sabatini, B. L., & Hochbaum, D. R. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2308652121 · Cited by 30
“…findings have suggested a potentially important clinical role for free T3 measurement, as well as benefits of combination liothyronine and levothyroxine therapy in highly symptomatic patients, which is consistent with an important role of age - related changes in T3 and the T3/T4 ratio (14, 51).”
BackgroundPlanck, T., Lantz, M., Perros, P., Papini, E., Attanasio, R., Nagy, E. V., & Hegedüs, L. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.795111 · Cited by 23
“org 2 L-T4 and L-T3, among other substances, is, in Sweden, only available with an individual license approved by the Swedish Medical Products Agency due to limited scientific evidence for its benefit (22, 23).”
BackgroundBrigante, G., Santi, D., Boselli, G., Margiotta, G., Corleto, R., Monzani, M. L., Craparo, A., Locaso, M., Sperduti, S., Roy, N., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad172 · Cited by 23
Casis, Ó., Echeazarra, L., Sáenz-Díez, B., & Gallego, M. (2023) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-023-01000-z · Cited by 22
“However, it has been shown that this treatment does not eliminate symptoms in up to 20% of patients, and therefore, the introduction of T3 is being discussed again [9, 29, 51], although its effect on arrhythmogenesis in humans still needs to be studied in depth.”
BackgroundCasula, S., Ettleson, M. D., & Bianco, A. C. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.04.003 · Cited by 21
Self-citationMolewijk, E., Fliers, E., Dreijerink, K. M. A., van Dooren, A. A., & Heerdink, E. R. (2024) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2024.100330 · Cited by 31
“This differs from studies where DTE users had a similar QoL as LT4 users, although DTE was preferred over LT4 [36,37].”
Implementation of thyroid-related patient-reported outcomes in routine clinical practice
Cramon, P. K., Bjørner, J. B., Grøenvold, M., Boesen, V. B., Bonnema, S. J., Hegedűs, L. D., Feldt‐Rasmussen, U., Rasmussen, Å. K., & Watt, T. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1000682 · Cited by 19
“Frontiers in Endocrinology 03 thyroid extract (45).”
Gene polymorphisms and thyroid hormone signaling: implication for the treatment of hypothyroidism
Penna, G., Salas-Lucia, F., Ribeiro, M. O., & Bianco, A. C. (2023) · Endocrine · doi:10.1007/s12020-023-03528-y · Cited by 20
“This seems to be particularly true for patients that exhibit residual symptoms while on therapy with LT4 [89], or when an association with the MCT10 SNP rs17606253 was also considered [90].”
Self-citationEttleson, M. D., Ibarra, S., Wan, W., Peterson, S., Laiteerapong, N., & Bianco, A. C. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad331 · Cited by 17
Self-citationTreatment Preferences in Patients With Hypothyroidism
de Lima Beltrão, F. E., Carvalhal, G., de Almeida Beltrão, D. C., de Lima Beltrão, F. E., Ribeiro, M. O., Ettleson, M. D., Ramos, H. E., & Bianco, A. C. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae651 · Cited by 16
Self-citationJiskra, J., Paleček, J., Attanasio, R., Hegedüs, L., Nagy, E. V., Papini, E., Perros, P., Negro, R., & Kršek, M. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01027-1 · Cited by 14
“), and combined therapy with LT4 and LT3 are limited [6, 12].”
BackgroundProgress Toward and Challenges Remaining for Thyroid Tissue Regeneration
Romitti, M., & Costagliola, S. (2023) · Endocrinology · doi:10.1210/endocr/bqad136 · Cited by 15
Nassar, M., Hassan, A., Ramadan, S., Desouki, M. T., Hassan, M. A., & Chaudhuri, A. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01612-6 · Cited by 12
“These indicators provide essential insights into the subjective experience of symptoms and overall well-being, reflecting the treatments’ effectiveness from the patient’s perspective [9].”
BackgroundResultInfluentialReal Practice Assessment of Persistent Symptoms After Initiation of Levothyroxine
Hidalgo, J., Vallejo, B. A., Soto Jacome, C., Ayala, I. N., Cordova, S., Duran, M., Golembiewski, E., Toro-Tobon, D., & Brito, J. P. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2023.10.132 · Cited by 12
Jonklaas, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.934003 · Cited by 13
“Anecdotal data (11, 16) and a post-hoc analysis of a recent trial (17) hint at benefits from animal thyroid products providing combination therapy and either synthetic or natural combination therapy respectively.”
BackgroundBahl, S., Taylor, P. N., Premawardhana, L. D., Stedman, M., Heald, A., Dayan, C. M., & Okosieme, O. E. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf449 · Cited by 11
Vargas‐Uricoechea, H., & Wartofsky, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179218 · Cited by 15
Riis, K. R., Larsen, C. B., & Bonnema, S. J. (2024) · Thyroid® · doi:10.1089/thy.2023.0649 · Cited by 10
Phan, G. Q., Yavuz, S., Stamatouli, A. M., Madan, R., Chen, S., Grover, A. C., Nilubol, N., Bedoya, P., Trankle, C. R., Markley, R., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1522753 · Cited by 9
The complexity of the relationship between thyroid disease and body weight
Jonklaas, J. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01190-0 · Cited by 10
Zhang, Y., Yang, J., Gong, Y., He, S., Wen, P., Jiang, Y., Jing, H., Zhu, B., & Li, L. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03665-5 · Cited by 10
“In contrast, oral synthetic levothyroxine (LT4) is currently the main treatment inter-nationally, but this therapy may result in abnormal weight loss in patients due to changes in liothyronine (LT3), LT4, or iodine levels [27].”
Ito, H., Fukuda, K., Ashida, K., Nagayama, A., Sako, T., Mizuochi, K., Kabashima, M., Yoshinobu, S., Iwata, S., Hasuzawa, N., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.838739 · Cited by 8
Penna, G. C., Bianco, A. C., & Ettleson, M. D. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad629 · Cited by 8
Self-citationBeltrão, F. E. D. L., Carvalhal, G., Meneghini, V., Matos, D. A. R., Beltrão, D. C. D. A., Andrade, B. A. R. M., Beltrão, F. N. D. L., Ramos, H. E., Ribeiro, M. O., Golovko, G., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf367 · Cited by 7
Self-citationRole of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism
Jonklaas, J. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.12.003 · Cited by 10
Optimizing the treatment of hypothyroidism
Bianco, A. C., & Taylor, P. N. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00989-7 · Cited by 9
Self-citationGottwald-Hostalek, U., & Tayrouz, Y. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2435460 · Cited by 6
Guglielmi, R., Mian, C., Novizio, R., Paoletta, A., Persichetti, A., Samperi, I., Scoppola, A., Bagnasco, M., Menis, E. D., Rimini, M. L. D., et al. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02652-y · Cited by 6
Jensen, C. Z., Isaksen, J. L., Ahlberg, G., OLESEN, M. S., Nygaard, B., Ellervik, C., & Kanters, J. K. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad556 · Cited by 8
Natural desiccated thyroid for the treatment of hypothyroidism?
Heald, A. H., Taylor, P., Premawardhana, L., Stedman, M., & Dayan, C. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1309159 · Cited by 5
Shared Decisionmaking in the Treatment of Hypothyroidism
Bianco, A. C. (2025) · Clinical Endocrinology · doi:10.1111/cen.15228 · Cited by 7
“Nonetheless, many patients benefit from the addition of LT3 to their treatment regiments even with the LT3 preparations available today [45].”
Self-citationAbood, B. H., & Alhussaynei, A. J. (2022) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs22167608 · Cited by 5
The Influence of Thyroid Dysfunction on Body Composition and Weight Trajectory
Jonklaas, J. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.11.012 · Cited by 6
Herbal remedies for hypothyroidism: A systematic review and meta-analysis.
Ghaffari-Saravi, F., & Jokar, A. (2025) · PubMed Central · doi:10.22088/cjim.16.1.1 · Cited by 8
Long-term outcomes of LT4/LT3 combination treatment for persistent hypothyroid symptoms
Nygaard, B., Jensen, C. Z., Jorsal, M. J., Medici, B. R., Steffensen, R., Carlé, A., & la Cour, J. L. (2025) · European Thyroid Journal · doi:10.1530/etj-24-0275 · Cited by 3
Levothyroxine Monotherapy: What Works Better for the Individual With Hypothyroidism?
Hennessey, J. V. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2022.12.013 · Cited by 4
Liu, A., Morrison, D., Hegedűs, L. D., Nagy, E. V., Papini, E., Perros, P., Attanasio, R., Negro, R., Uum, S. H. M. V., Nygaard, B., et al. (2025) · Clinical Endocrinology · doi:10.1111/cen.70009 · Cited by 4
“Indeed, data from two randomized controlled trials did not show significant differences in QoL or symptom scores between DTE and other thyroid hormone formulations [52, 53].”
Socioeconomic influence on treatment with liothyronine and desiccated thyroid extract in Denmark
la Cour, J. L., Møllehave, L. T., Medici, B. R., Jensen, C. Z., Bjerregaard, A. A., & Nygaard, B. (2022) · European Thyroid Journal · doi:10.1530/etj-22-0149 · Cited by 3
Hoang, T. D., Patel, A. A., Spiro, A. J., Watson, N. L., & Shakir, M. K. M. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.09.007 · Cited by 2
Self-citationGenetics of Thyroid Function: Relevance for Biology and Disease Management
Sterenborg, R. B. T. M., Peeters, R. P., Visser, W. E., Kuś, A., Smit, J. W. A., Teumer, A., & Medici, M. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf491 · Cited by 3
Rethinking strategies for solving thyroid dysfunction at the heart of cardiovascular disease
Rajagopalan, V., Ojamaa, K., & Gerdes, A. M. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01351-x · Cited by 3
Year in Thyroidology—Recent Developments and Future Challenges: Clinical Science Review
Haymart, M. R. (2021) · Thyroid · doi:10.1089/thy.2021.0562 · Cited by 2
“(5).”
Caron, P. J. (2023) · Annales d Endocrinologie · doi:10.1016/j.ando.2023.05.005 · Cited by 2
Jonklaas, J. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2492789 · Cited by 2
Gu, Y., Song, Z., Li, Q., Wang, J., Song, Y., Meng, G., Wu, H., Zhang, S., Wang, X., Zhang, J., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad025 · Cited by 2
Akan, G., Adolf, I. C., Colak, A., Acar, S., Öncü, F., Yeşilbursa, D., Türkcan, S., Atalar, F., & Gazioglu, S. B. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70694 · Cited by 2
“Importantly, administration of liothyronine, a synthetic T3 hormone, enhances T3 signalling in the brain and ameliorates cognitive function in those mice [28].”
Thyroid hormones, iodine, and iodides, and antithyroid drugs
Schalliol, L. A., & Pittman, J. M. (2022) · Side effects of drugs annual · doi:10.1016/bs.seda.2022.08.001 · Cited by 2
Hypothyroidism, diabetes, and cardiovascular disease
England, M. L., & Gerrard, J. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95469-3.00004-8 · Cited by 4
Phase 1 Clinical Trial of Poly-Zinc-Liothyronine Demonstrates Slow-Release Serum T 3 Kinetics
McAninch, E. A. (2022) · Clinical Thyroidology · doi:10.1089/ct.2022;34.9-12 · Cited by 2
“This is consistent with other recent studies that have not demonstrated harm with L-T 3 use at doses that maintain a normal serum TSH (6,9,10).”
Self-citationBonnema, S. J., Riis, K. R., Jensen, C. Z., Thvilum, M., & Nygaard, B. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab778 · Cited by 2
Investigation of Eating Behaviors in Euthyroid Patients With Hashimoto’s Thyroiditis
Altuntaş, S. Ç. (2025) · Cureus · doi:10.7759/cureus.81814 · Cited by 1
“Therefore, studies have explored the use of triiodothyronine extract or LT4/LT3 combinations [23,24].”
Is euthyroidism within reach for all?
Jonklaas, J. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2267120 · Cited by 2
“…include that combination therapy may be more beneficial in the subgroup of patients who are most symptomatic while taking LT4 monotherapy [29,30] and in those that have less residual endogenous thyroid function [31], that patients may prefer T3 doses that result in iatrogenic…”
BackgroundQuality of life in hypothyroid subjects treated with levothyroxine: a cross-sectional study
Rezaeizade, H., Shabestari, M., Hazar, N., Ghadiri‐Anari, A., Mehrali, M., Salehi‐Shadkami, M., & Azizi, R. (2026) · Thyroid Research · doi:10.1186/s13044-026-00307-5 · Cited by 2
“Panicker et al. reported that polymorphism negatively affected QoL [24], whereas Shakir et al. in the Netherlands found no such association [26].”
Ghasemian, M., Karajizadeh, M., Yousefi, M. R., Yadollahi, M., & Paydar, S. (2025) · Journal of Voice · doi:10.1016/j.jvoice.2025.02.033 · Cited by 1
Clinical thyroidology: beyond the 1970s’ TSH-T4 Paradigm
Lindner, H. H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1529791 · Cited by 2
“Patients with residual symptoms on T4 prefer T4/T3 and DTE (50 – 53).”
Chavez, C. P., & Ospina, N. S. (2021) · Clinical Thyroidology · doi:10.1089/ct.2021;33.346-349
“The current study aimed to evaluate the clinical effects of DTE, L-T 4 , and combination therapy (L-T 4 and L-T 3 ) in patients with hypothyroidism; the study provides preliminary evaluation of treatment differences among recommended subgroups of interest (11).”
Shakir, M. K. M., Brooks, D. I., McAninch, E. A., Fonseca, T. D. L., Mai, V. Q., Bianco, A. C., & Hoang, T. D. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab779
Self-citationDer natürliche Schilddrüsenextrakt – eine echte Alternative?
Hermann, A., & Brada-Wallbrecher, J. (2022) · Erfahrungsheilkunde · doi:10.1055/a-1789-1280
A Brief History of Glandular Therapy: More Than Just Thyroid.
Isaacs, L. L. (2023) · PubMed Central
Endo, M. (2023) · Clinical Thyroidology · doi:10.1089/ct.2023;35.316-318
Comparison of Often Used Analysis Methods for Rank-Ordered Data
Demir, S. (2023) · International Journal of Progressive Education · doi:10.29329/ijpe.2023.603.1
Safety of Levothyroxine plus Liothyronine in Postsurgical Hypothyroidism
McAninch, E. A. (2024) · Clinical Thyroidology · doi:10.1089/ct.2024;36.9-11
Self-citationTerapia dell’ipotiroidismo primitivo: un ormone o due ormoni?
Brigante, G., Ceccarini, G., Porcelli, T., Santini, F., Salvatore, D., Simoni, M., & Bartalena, L. (2024) · L Endocrinologo · doi:10.1007/s40619-024-01429-4
“Un’altra ipotesi è che tale approccio terapeutico sia di be-neficio solo per i pazienti che lamentano una maggiore persi-stenza di sintomi nonostante il trattamento con L-T4, quale che ne sia la causa [18].”
ATUALIZAÇÕES NO DIAGNÓSTICO E MANEJO DO HIPOTIREOIDISMO: UMA REVISÃO INTEGRATIVA
Queiroz, S. M., Bessa, F. D. O., Filho, A. F. A., Lima, A. C. D. S., Reis, B. E. S., Maia, I. B., de Freitas, T. C. A., Leal, L. A., de Freitas, A. C., Kretli, J. S., et al. (2024) · Revista Interdisciplinar de Ciências da Saúde. · doi:10.70209/rics.v1i1.19
Cardiac Tamponade: A Late and Rare Finding of Hypothyroidism
Janabi, T. A., Gupta, V., Naintara, F., Seidenberg, J., & Hoskote, A. (2024) · Cureus · doi:10.7759/cureus.70617 · Cited by 1
Ghaznavi, S. A. (2024) · Clinical Thyroidology · doi:10.1089/ct.2024;36.365-368
“13,14 In one unblinded cohort study, 93% of participants self-reported an improved QoL after switching to DTE.”
Guglielmi, R., Mian, C., Andreoli, C., Bagnasco, M., Boniardi, M., Menis, E. D., Rimini, M. L. D., Tina, D., Fiorentini, G., Locantore, P., et al. (2025) · L Endocrinologo · doi:10.1007/s40619-025-01601-4
Hoermann, R., & Dietrich, J. W. (2025) · Springer eBooks · doi:10.1007/978-981-96-3682-2_11
Reverse T3 in patients with hypothyroidism on different thyroid hormone replacement
Wilson, J. B., Hoang, T. D., Lee, M. L., Epstein, M., & Friedman, T. C. (2025) · PLoS ONE · doi:10.1371/journal.pone.0325046 · Cited by 1
Self-citationPrecision Thyroid Hormone Therapy for Hypothyroidism
Bianco, A. C., & Beltrão, F. E. D. L. (2025) · Springer eBooks · doi:10.1007/978-3-031-89650-7_24
Self-citationPeterman, K., Tacata, R. H. N., Cerezo, N., & Casimiro, I. (2025) · Journal of Clinical and Translational Endocrinology Case Reports · doi:10.1016/j.jecr.2025.100201
Nassar, M., Hassan, A., Ramadan, S., Desouki, M., Hassan, M. A., & Chaudhuri, A. (2024) · Figshare · doi:10.6084/m9.figshare.26733783
Wang, Y., Zhu, J., Li, Z., Yu, F., Fu, Y., Gao, H., Wang, M., Yuan, L., Zheng, L., & He, Q. (2026) · Cell Transplantation · doi:10.1177/09636897261418754
THE ROLE OF MICRONUTRIENTS AND SUPPLEMENTS IN HYPOTHYROIDISM MANAGEMENT: A LITERATURE REVIEW
Wróbel, Z., Torbacka, K., Kaczor, J., Torbacka, M., Rozkosz, K., Wróbel, N., Jakubik, O., Podlejska, P., Sosin, A., & Bednarz, W. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4434
Al‐Bitar, A., Alassaf, B., Asfour, B., Isstaif, J., & Al‐Hawasli, M. (2026) · Case Reports in Neurology · doi:10.1159/000552367
“Second-line therapies, indicated in cases resistant to levothyroxine, include combination therapy with liothyronine and levothyroxine or desiccated thyroid extract [22].”
Геннадьевна, Р. Е., Моргунова, Т. Б., Ryzhkov, I., & Fadeyev, V. (2026) · Vrach · doi:10.29296/25877305-2026-05-13
Nagayama, Y., Tachibana, S., Fukuda, T., Tatsushima, D., Mori, Y., Shindo, H., Takahashi, H., Satoh, S., Nakashima, M., & Yamashita, H. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag220
Torre, S. C. D. L., Shakir, M. K. M., Davis, L. A., & Hoang, T. D. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.07.020
Self-citationHashimoto's thyroiditis: two decades on
Duntas, L. H., & Effraimidis, G. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00189-0
Metadata
- Authors
- Shakir, M. K. M., Brooks, D. I., McAninch, E. A., Fonseca, T. L., Mai, V. Q., Bianco, A. C., & Hoang, T. D.
- Affiliations
- Uniformed Services University of the Health Sciences (US)
- Walter Reed National Military Medical Center (US)
- Rush University Medical Center (US)
- University of Chicago (US)
- Corresponding author
- Hoang, Thanh D
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2021-06-29
- Volume
- 106
- Issue
- 11
- Pages
- e4400-e4413
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC8530721
- OpenAlex
- W3174863317
- Cited by
- 92
- References
- 32
- Citations by year
- 2026: 7 · 2025: 25 · 2024: 17 · 2023: 21 · 2022: 16 · 2021: 6
- FWCI
- 11.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Walter Reed National Military Medical Center Institutional Research Board
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Keywords
- hypothyroidism, levothyroxine, desiccated thyroid extract, liothyronine, thyroid hormone replacement, comparative effectiveness, thyroid symptoms, quality of life, depression, memory, heart rate, thyroid-stimulating hormone, treatment preferences
- MeSH terms
- Adult, Aged, Desiccation, Double-Blind Method, Female, Humans, Hypothyroidism, Male, Middle Aged, Placebos, Prospective Studies, Quality of Life, Surveys and Questionnaires, Thyroid Gland, Thyroxine, Tissue Extracts, Triiodothyronine, Treatment Outcome, Cross-Over Studies, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.